Fortrea Holdings (FTRE) Common Equity (2022 - 2026)
Fortrea Holdings (FTRE) posted Common Equity of $525.9 million for Q1 2026, down 6.67% on a QoQ basis from $563.5 million in Q4 2025, and down 38.76% year-over-year from $858.8 million in Q1 2025.
Fortrea Holdings (FTRE) Common Equity (2022 - 2026) Analysis & Trends
Fortrea Holdings' Common Equity history runs 5 years deep, the most recent figure standing at $525.9 million for Q1 2026.
- Quarterly Common Equity fell 38.76% year-over-year to $525.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $525.9 million (down 38.76% YoY) and the FY2025 annual result came in at $563.5 million, down 58.64% from the prior year.
- Common Equity was $525.9 million for Q1 2026 at Fortrea Holdings, down from $563.5 million in the prior quarter.
- Across five years, Common Equity topped out at $3.4 billion in Q1 2023 and bottomed at $525.9 million in Q1 2026.
- A 5-year average of $1.6 billion and a median of $1.5 billion in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity decreased 10.47% — and 2025, when it plunged 61.63%.
- Fortrea Holdings' Common Equity stood at $3.3 billion in 2022, then tumbled by 48.68% to $1.7 billion in 2023, then dropped by 20.52% to $1.4 billion in 2024, then tumbled by 58.64% to $563.5 million in 2025, then declined by 6.67% to $525.9 million in 2026.
- Business Quant data shows FTRE's Common Equity at $525.9 million in Q1 2026, $563.5 million in Q4 2025, and $580.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -98.34 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.76 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.36 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.50 Bn |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | 525.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 525.90 Mn |
| Dec 31, 2025 | 563.50 Mn |
| Sep 30, 2025 | 580.80 Mn |
| Jun 30, 2025 | 589.20 Mn |
| Mar 31, 2025 | 858.80 Mn |
| Dec 31, 2024 | 1.36 Bn |
| Sep 30, 2024 | 1.51 Bn |
| Jun 30, 2024 | 1.46 Bn |
| Mar 31, 2024 | 1.59 Bn |
| Dec 31, 2023 | 1.71 Bn |
| Sep 30, 2023 | 1.69 Bn |
| Jun 30, 2023 | 1.75 Bn |
| Mar 31, 2023 | 3.40 Bn |
| Dec 31, 2022 | 3.34 Bn |
| Jun 30, 2022 | 3.30 Bn |